Show simple item record

dc.contributor.authorWalsh, Martin J.
dc.contributor.authorBrimacombe, Kyle R.
dc.contributor.authorVeith, Henrike
dc.contributor.authorBougie, James M.
dc.contributor.authorDaniel, Thomas
dc.contributor.authorLeister, William
dc.contributor.authorCantley, Lewis C.
dc.contributor.authorVander Heiden, Matthew G.
dc.contributor.authorShen, Min
dc.contributor.authorAuld, Douglas S.
dc.contributor.authorThomas, Craig J.
dc.contributor.authorBoxer, Matthew B.
dc.contributor.authorIsraelsen, William James
dc.date.accessioned2015-10-07T15:04:46Z
dc.date.available2015-10-07T15:04:46Z
dc.date.issued2011-09
dc.date.submitted2011-08
dc.identifier.issn0960894X
dc.identifier.urihttp://hdl.handle.net/1721.1/99178
dc.description.abstractCompared to normal differentiated cells, cancer cells have altered metabolic regulation to support biosynthesis and the expression of the M2 isozyme of pyruvate kinase (PKM2) plays an important role in this anabolic metabolism. While the M1 isoform is a highly active enzyme, the alternatively spliced M2 variant is considerably less active and expressed in tumors. While the exact mechanism by which decreased pyruvate kinase activity contributes to anabolic metabolism remains unclear, it is hypothesized that activation of PKM2 to levels seen with PKM1 may promote a metabolic program that is not conducive to cell proliferation. Here we report the third chemotype in a series of PKM2 activators based on the 2-oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamide scaffold. The synthesis, structure activity relationships, selectivity and notable physiochemical properties are described.en_US
dc.description.sponsorshipNational Human Genome Research Institute (U.S.) (Molecular Libraries Initiative of the NIH Roadmap for Medical Research)en_US
dc.language.isoen_US
dc.publisherElsevieren_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/j.bmcl.2011.08.114en_US
dc.rightsCreative Commons Attribution-Noncommercial-NoDerivativesen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.sourcePMCen_US
dc.title2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinaseen_US
dc.typeArticleen_US
dc.identifier.citationWalsh, Martin J., Kyle R. Brimacombe, Henrike Veith, James M. Bougie, Thomas Daniel, William Leister, Lewis C. Cantley, et al. “2-Oxo-N-Aryl-1,2,3,4-Tetrahydroquinoline-6-Sulfonamides as Activators of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase.” Bioorganic & Medicinal Chemistry Letters 21, no. 21 (November 2011): 6322–6327.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorIsraelsen, William J.en_US
dc.contributor.mitauthorVander Heiden, Matthew G.en_US
dc.relation.journalBioorganic & Medicinal Chemistry Lettersen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsWalsh, Martin J.; Brimacombe, Kyle R.; Veith, Henrike; Bougie, James M.; Daniel, Thomas; Leister, William; Cantley, Lewis C.; Israelsen, William J.; Vander Heiden, Matthew G.; Shen, Min; Auld, Douglas S.; Thomas, Craig J.; Boxer, Matthew B.en_US
dc.identifier.orcidhttps://orcid.org/0000-0002-6702-4192
mit.licensePUBLISHER_CCen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record